China Uniquely Suited To Build Pharma 3.0 From The Ground Up As Healthcare Reform Rolls Out
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - As the pharmaceutical industry begins to embrace new business models that utilize the newest advances in information technology to achieve better health outcomes, China may be uniquely suited to implement such a system from the ground up, Ernst & Young said during a life sciences roundtable discussion with local reporters in Shanghai March 25
You may also be interested in...
Reimbursement Expansion To Fuel China Device Growth In 2011 (Part 2 of 2)
[Editor's note: This is part two of a two-part story. Part one appeared in PharmAsia News, Feb. 22, 2011.]
China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).